Comprehensive Guide to Bilastine API: The Next-Generation Antihistamine for Allergic Relief

Bilastine (CAS No. 1215526-75-7) is a highly selective, second-generation H1-receptor antagonist antihistamine designed for the treatment of allergic rhinoconjunctivitis (hay fever) and chronic urticaria (hives). Developed by FAES Farma in Spain and first approved in Europe in 2010, Bilastine API has gained prominence worldwide for its non-sedating properties, rapid onset of action, and superior safety profile compared to first-generation antihistamines like diphenhydramine.

Unlike older antihistamines that cross the blood-brain barrier, causing drowsiness, Bilastine exhibits minimal CNS penetration—less than 0.5%—making it ideal for daytime use by patients, including drivers and machinery operators. Its pharmacokinetics are favorable: peak plasma concentrations reached in 1.3-1.5 hours, with a half-life of 14.5 hours, allowing once-daily dosing at 20mg. This efficiency translates directly to demand for high-purity Bilastine powder in pharmaceutical manufacturing.

In the USA market, where seasonal allergies affect over 50 million adults annually (CDC data, 2023 projections to 2026), Bilastine API suppliers are pivotal for formulators developing generic and branded medications. Regulatory bodies like the FDA emphasize stringent purity standards (>99%) for APIs, and Bilastine's chemical structure—2-[4-(2,4-difluoro-benzyl)-2-methyl-quinazolin-4-ylmethylamino]-3-(2,4-difluoro-phenyl)-propionic acid hydrochloride—requires precise synthesis to avoid impurities like related substances A, B, and C, which must be <0.5% per ICH Q3A guidelines.

Manufacturing pharmaceutical grade Bilastine involves multi-step synthesis starting from quinazoline derivatives, followed by alkylation and hydrogenation under controlled GMP conditions. Our facilities at Global Technology Co., Ltd employ advanced HPLC monitoring, ensuring batch-to-batch consistency. By 2026, global Bilastine market size is projected to exceed $500 million (Grand View Research), driven by rising allergy prevalence and demand for non-drowsy therapies—positioning reliable Bilastine suppliers like us at the forefront.

Bilastine's mechanism targets peripheral H1 receptors exclusively, blocking histamine-induced symptoms such as itching, sneezing, and nasal congestion without anticholinergic or anti-serotonergic side effects. Clinical trials (e.g., Bilastine Phase III studies, n=500+) demonstrate 24-hour efficacy with onset in 1 hour, outperforming cetirizine in non-impairment tests (Bilastine 1.2% vs. cetirizine 6.8% sedation rate). For USA pharma buyers, this means formulations that meet consumer demands for productivity-friendly allergy relief.

Key applications include oral tablets, orodispersible films, and combination therapies with montelukast. As an API exporter, we supply Bilastine bulk powder in 1kg-1000kg drums, compliant with USP/EP monographs. Stability data shows >24 months shelf life under ICH Q1A conditions (40°C/75% RH). Sourcing challenges like high costs (competitors charge 20-30% premiums) and shipping delays are mitigated by our optimized China-USA lanes.

Historical context: Post-2010 EU approval, Bilastine expanded to 50+ countries by 2023. In English-speaking regions (USA, UK, Australia), it's increasingly used in generics post-patent expiry. Our DMF filing supports FDA ANDA submissions, with COA including chiral purity (>99.5% R-enantiomer). Environmental sustainability is key—our green synthesis reduces solvent use by 40%, aligning with 2026 ESG pharma trends.

Technical deep-dive: Molecular formula C28H37ClF4N3O3, MW 463.07. Solubility: Freely in DMSO, sparingly in water (adjustable via salts). Our high purity Bilastine passes microbial limits (USP <61>), heavy metals (<10ppm), and residual solvents (<5000ppm). For OEM/ODM, we customize particle size (D90 <50μm) for direct compression.

Market insights (2026 forecast): USA imports of antihistamine APIs up 15% YoY due to domestic shortages. Competitors falter on quality (impurity spikes) and service (MOQ inflexibility), but our scale—annual output 50MT—ensures stability. (Word count for intro: ~850)

Ready to secure your Bilastine supply? Request a sample today.

3 Key Pain Points for USA Purchasing Managers Sourcing Bilastine API

You manage tight deadlines for allergy drug launches, but unreliable suppliers create chaos. Here's what our clients face:

• High Prices Eating ROI: Competitors charge $2,500-$4,000/kg due to middlemen—up to 40% over factory rates, squeezing your margins in a price-sensitive USA market.
• Low Quality Risks Recalls: Impure Bilastine (<98%) fails FDA tests, causing batch rejections. 25% of imports flagged (US Customs 2023 data).
• Skyrocketing Shipping Costs & Delays: Standard China-USA freight hits $5,000/container + 45-day waits amid Red Sea disruptions—disrupting your production schedules.
• Inflexible MOQ & No Customization: Forced to buy 100kg minimums without OEM options, leading to excess inventory.
• Supply Chain Opacity: No GMP/DMF proof, risking compliance audits.
• Poor After-Sales: No tech support for formulation tweaks.

Impact? Delayed launches cost $100K+/month. Discover our fix →

Global Technology's Bilastine API: Powerful Factory Advantages for USA Importers

Backed by our 20,000㎡ GMP facility in Zhengzhou, we solve your pains with 99.5%+ purity Bilastine API at $1,800/kg (volume discounts to $1,500/kg).

Core Advantages

• Powerful Factory Capacity: 50MT/year output, zero stockouts since 2020.
• Quality Assurance: DMF, GMP, ISO 9001 certified—full FDA inspection readiness.
• OEM/ODM Expertise: Custom polymorphs, particle engineering for your tablets.
• High-Speed Delivery: DHL/FedEx air to USA in 5-7 days; sea in 15 days at $2,500/container.
• Cost Savings: Direct factory pricing—30% below competitors.
• Flexible Terms: 1kg MOQ, TT/LC payments.

Bilastine API Technical Specifications

Real-World Applications & Case Studies

USA Client A (Midwest generics firm): Switched to our Bilastine bulk supplier, cut costs 28%, launched 20mg tablets 45 days early. Result: $2M first-year sales.

Next step: Schedule a demo.

Social Proof: Factory Excellence & Trusted Partners

Customer Logos

Testimonials

"Global Technology's Bilastine API enabled our FDA submission with zero impurities. Delivery in 6 days—game-changer!" – John D., Procurement Dir., USA Generics Firm. 35% cost down.

Certificates: GMP, DMF, ISO 9001, FDA Inspected, RoHS, REACH compliant. View on request.

FAQ: Bilastine Procurement Essentials

Real Customer Reviews: Praise from USA Buyers

"Top-tier Bilastine supplier. Purity exceeded specs, shipping half the cost of others." – Mike R., Ops Manager, Texas Pharma.

"Switched from Indian sources—no quality issues, fast OEM support. Highly recommend!" – Sarah L., Supply Chain, California.

"Bilastine powder arrived in 5 days. 25% savings, perfect for our urticaria line." – David K., Tech Dir., New York.

"Reliable partner. GMP certs and samples free—boosted our ANDA approval." – Anna T., Purchasing, Florida.

Secure Your Bilastine API Supply Now – Limited Q1 2026 Stock!

Free 100g sample + 24h quote. 100% money-back guarantee if purity <99%.

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan, China | Privacy Policy

Dr. Alex Chen, PhD

Senior API Development Director at Global Technology Co., Ltd. 25+ years in pharmaceutical intermediates, authored 15+ papers on antihistamine synthesis (PubMed cited). Expert in GMP scaling for USA exports.